Src family kinases and their role in hematological malignancies

References

• Warmuth M, Bergmann M, Prieß A, et al. The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J Biol Chem 1997;272:33260–33270.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li S. Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells. Protein Cell 2013;4:186–196.
   PubMed Web of Science ®Google Scholar
• Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003;101:690–698.
   PubMed Web of Science ®Google Scholar
• Hu Y, Liu Y, Pelletier S, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004;36:453–461.
   PubMed Web of Science ®Google Scholar
• Wu J, Meng F, Lu H, et al. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood 2008;111:3821–3829.
   PubMed Web of Science ®Google Scholar
• Chong YP, Ia KK, Mulhern TD, et al. Endogenous and synthetic inhibitors of the Src-family protein tyrosine kinases. Biochim Biophys Acta 2005;1754:210–220.
   PubMed Web of Science ®Google Scholar
• Chong YP, Mulhern TD, Cheng HC. C-terminal Src kinase (CSK) and CSK-homologous kinase (CHK)–endogenous negative regulators of Src-family protein kinases. Growth Factors 2005;23:233–244.
   PubMed Web of Science ®Google Scholar
• Ia KK, Mills RD, Hossain MI, et al. Structural elements and allosteric mechanisms governing regulation and catalysis of CSK-family kinases and their inhibition of Src-family kinases. Growth Factors 2010;28:329–350.
   PubMed Web of Science ®Google Scholar
• Okada M. Regulation of the SRC family kinases by Csk. Int J Biol Sci 2012;8:1385–1397.
   PubMed Web of Science ®Google Scholar
• Xu W, Doshi A, Lei M, et al. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell 1999;3:629–638.
   PubMed Web of Science ®Google Scholar
• Schindler T, Sicheri F, Pico A, et al. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol Cell 1999;3:639–648.
   PubMed Web of Science ®Google Scholar
• Amrein PC. The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms. Leuk Lymphoma 2011;52:754–763.
   PubMed Web of Science ®Google Scholar
• Congleton J, MacDonald R, Yen A. Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells. Leukemia 2012;26:1180–1188.
   PubMed Web of Science ®Google Scholar
• Distler JH, Distler O. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. Rheumatology (Oxford) 2008;47(Suppl. 5):v10–v11.
   Google Scholar
• Miranda MB, Johnson DE. Signal transduction pathways that contribute to myeloid differentiation. Leukemia 2007;21:1363–1377.
   PubMed Web of Science ®Google Scholar
• Chan P-C, Chen H-C. p120RasGAP-mediated activation of c-Src is critical for oncogenic Ras to induce tumor invasion. Cancer Res 2012;72:2405–2415.
   PubMed Web of Science ®Google Scholar
• Poincloux R, Al Saati T, Maridonneau-Parini I, et al. The oncogenic activity of the Src family kinase Hck requires the cooperative action of the plasma membrane- and lysosome-associated isoforms. Eur J Cancer 2009;45:321–327.
   PubMed Web of Science ®Google Scholar
• Yoon SG, Cheong HJ, Kim SJ, et al. Src family kinase inhibitor PP2 has different effects on all-trans-retinoic acid or arsenic trioxide-induced differentiation of an acute promyelocytic leukemia cell line. Cancer Res Treat 2013;45:126–133.
   PubMedGoogle Scholar
• Fraser CK, Lousberg EL, Guerin LR, et al. Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo. Cancer Biol Ther 2010;10:715–727.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007;6:834–848.
   PubMed Web of Science ®Google Scholar
• Howlett CJ, Robbins SM. Membrane-anchored Cbl suppresses Hck protein-tyrosine kinase mediated cellular transformation. Oncogene 2002;21:1707–1716.
   PubMed Web of Science ®Google Scholar
• Broudy VC, Lin NL, Liles WC, et al. Signaling via Src family kinases is required for normal internalization of the receptor c-Kit. Blood 1999;94:1979–1986.
   PubMed Web of Science ®Google Scholar
• Linnekin D. Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol 1999;31:1053–1074.
   PubMed Web of Science ®Google Scholar
• Zhang T, Liu S, Yang P, et al. Fibronectin maintains survival of mouse natural killer (NK) cells via CD11b/Src/beta-catenin pathway. Blood 2009;114:4081–4088.
   PubMed Web of Science ®Google Scholar
• Konig H, Copland M, Chu S, et al. Effects of dasatinib on Src kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res 2008; 68:9624–9633.
   PubMed Web of Science ®Google Scholar
• Anderson SM, Carroll PM, Lee FD. Abrogation of IL-3 dependent growth requires a functional v-src gene product: evidence for an autocrine growth cycle. Oncogene 1990;5:317–325.
   PubMed Web of Science ®Google Scholar
• Tilbrook PA, Ingley E, Williams JH, et al. Lyn tyrosine kinase is essential for erythropoietin-induced differentiation of J2E erythroid cells. EMBO J 1997;16:1610–1619.
   PubMed Web of Science ®Google Scholar
• Kubota Y, Tanaka T, Kitanaka A, et al. Src transduces erythropoietin-induced differentiation signals through phosphatidylinositol 3-kinase. EMBO J 2001;20:5666–5677.
   PubMed Web of Science ®Google Scholar
• Bridoux L, Etique N, Lambert E, et al. A crucial role for Lyn in TIMP-1 erythroid cell survival signalling pathway. FEBS Lett 2013;587:1524–1528.
   PubMed Web of Science ®Google Scholar
• Ingley E. Functions of the Lyn tyrosine kinase in health and disease. Cell Commun Signal 2012;10:21.
   PubMed Web of Science ®Google Scholar
• Nishizumi H, Taniuchi I, Yamanashi Y, et al. Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice. Immunity 1995;3:549–560.
   PubMed Web of Science ®Google Scholar
• Wang J, Koizumi T, Watanabe T. Altered antigen receptor signaling and impaired Fas-mediated apoptosis of B cells in Lyn-deficient mice. J Exp Med 1996;184:831–838.
   PubMed Web of Science ®Google Scholar
• Chan VWF, Meng F, Soriano P, et al. Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation. Immunity 1997;7:69–81.
   PubMed Web of Science ®Google Scholar
• Gamas P, Marchetti S, Puissant A, et al. Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells. Leukemia 2009;23:1500–1506.
   PubMed Web of Science ®Google Scholar
• Williams NK, Lucet IS, Klinken SP, et al. Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state. J Biol Chem 2009;284:284–291.
   PubMed Web of Science ®Google Scholar
• Saito Y, Yuki H, Kuratani M, et al. A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo. Sci Transl Med 2013;5: 181ra52.
   PubMed Web of Science ®Google Scholar
• Gao Y, Howard A, Ban K, et al. Oxidative stress promotes transcriptional up-regulation of Fyn in BCR-ABL1-expressing cells. J Biol Chem 2009;284:7114–7125.
   PubMed Web of Science ®Google Scholar
• Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 2004;23: 7990–8000.
   PubMed Web of Science ®Google Scholar
• Cooper JC, Shi M, Chueh FY, et al. Enforced SOCS1 and SOCS3 expression attenuates Lck-mediated cellular transformation. Int J Oncol 2010;36:1201–1208.
   Google Scholar
• Fan G, Simmons MJ, Ge S, et al. Defective ubiquitin-mediated degradation of antiapoptotic Bfl-1 predisposes to lymphoma. Blood 2010;115:3559–3569.
   PubMed Web of Science ®Google Scholar
• Abraham KM, Levin SD, Marth JD, et al. Thymic tumorigenesis induced by overexpression of p56lck. Proc Natl Acad Sci USA 1991; 88:3977–3981.
   PubMed Web of Science ®Google Scholar
• Harder KW, Parsons LM, Armes J, et al. Gain- and loss-of-function Lyn mutant mice define a critical inhibitory role for Lyn in the myeloid lineage. Immunity 2001;15:603–615.
   PubMed Web of Science ®Google Scholar
• Lowell C, Niwa M, Soriano P, et al. Deficiency of the Hck and Src tyrosine kinases results in extreme levels of extramedullary hematopoiesis. Blood 1996;87:1780–17892.
   PubMed Web of Science ®Google Scholar
• Mermel CH, McLemore ML, Liu F, et al. Src family kinases are important negative regulators of G-CSF-dependent granulopoiesis. Blood 2006;108:2562–2568.
   PubMed Web of Science ®Google Scholar
• Sirvent A, Benistant C, Roche S. Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer. Am J Cancer Res 2012;2:357–371.
   PubMed Web of Science ®Google Scholar
• Shields BJ, Wiede F, Gurzov EN, et al. TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers. Mol Cell Biol 2013;33:557–570.
   PubMedGoogle Scholar
• Wang B, Lemay S, Tsai S, et al. SH2 domain-mediated interaction of inhibitory protein tyrosine kinase Csk with protein tyrosine phosphatase-HSCF. Mol Cell Biol 2001;21:1077–1088.
   PubMed Web of Science ®Google Scholar
• Kawabuchi M, Satomi Y, Takao T, et al. Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases. Nature 2000;404:999–1003.
   PubMed Web of Science ®Google Scholar
• Brdicka T, Pavlistova D, Leo A, et al. Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein tyrosine kinase csk and is involved in regulation of T cell activation. J Exp Med 2000;191:1591–1604.
   PubMed Web of Science ®Google Scholar
• Kuiper RP, Schoenmakers EF, van Reijmersdal SV, et al. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia 2007;21:1258–1266.
   PubMed Web of Science ®Google Scholar
• Chong YP, Mulhern TD, Zhu HJ, et al. A novel non-catalytic mechanism employed by the C-terminal Src-homologous kinase to inhibit Src-family kinase activity. J Biol Chem 2004;279:20752–20766.
   PubMed Web of Science ®Google Scholar
• Chong YP, Chan AS, Chan KC, et al. C-terminal Src kinase-homologous kinase (CHK), a unique inhibitor inactivating multiple active conformations of Src family tyrosine kinases. J Biol Chem 2006;281:32988–32999.
   PubMed Web of Science ®Google Scholar
• Akagi T, Ogawa S, Dugas M, et al. Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype. Haematologica 2009;94:213–223.
   PubMed Web of Science ®Google Scholar
• Tan SY, Ooi AS, Ang MK, et al. Nuclear expression of MATK is a novel marker of type II enteropathy-associated T-cell lymphoma. Leukemia 2011;25:555–557.
   PubMed Web of Science ®Google Scholar
• Kleppe M, Soulier J, Asnafi V, et al. PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia. Blood 2011;117:7090–7098.
   PubMed Web of Science ®Google Scholar
• Amsberg GK, Koschmieder S. Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia. Onco Targets Ther 2013;6:99–106.
   PubMed Web of Science ®Google Scholar
• Chen Y. Are SRC family kinases responsible for imatinib- and dasatinib-resistant chronic myeloid leukemias?Leuk Res 2011; 35:27–29.
   PubMed Web of Science ®Google Scholar
• Wilson MB, Schreiner SJ, Choi H-J, et al. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene 2002; 21:8075–8088.
   PubMed Web of Science ®Google Scholar
• Pene-Dumitrescu T, Peterson LF, Donato NJ, et al. An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259. Oncogene 2008;27:7055–7069.
   PubMed Web of Science ®Google Scholar
• Meyn MA, Wilson MB, Abdi FA, et al. Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity. J Biol Chem 2006;281:30907–30916.
   PubMed Web of Science ®Google Scholar
• Vazquez-Franco JE, Reyes-Maldonado E, Vela-Ojeda J, et al. Src, Akt, NF-kappaB, BCL-2 and c-IAP1 may be involved in an anti-apoptotic effect in patients with BCR-ABL positive and BCR-ABL negative acute lymphoblastic leukemia. Leuk Res 2012;36:862–867.
   PubMed Web of Science ®Google Scholar
• Klejman A, Schreiner SJ, Nieborowska-Skorska M, et al. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J 2002;21:5766–5774.
   PubMed Web of Science ®Google Scholar
• Danhauser-Riedl S, Warmuth M, Druker BJ, et al. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res 1996;56:3589–3596.
   PubMed Web of Science ®Google Scholar
• Hayette S, Chabane K, Michallet M, et al. Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients. Leuk Res 2011;35:38–43.
   PubMed Web of Science ®Google Scholar
• Rubbi L, Titz B, Brown L, et al. Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling. Sci Signal 2011;4: ra18.
   PubMed Web of Science ®Google Scholar
• Breccia M, Salaroli A, Molica M, et al. Systematic review of dasatinib in chronic myeloid leukemia. Onco Targets Ther 2013; 6:257–265.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Takeuchi M, Takeda Y, et al. Identification of a novel TEL-Lyn fusion gene in primary myelofibrosis. Leukemia 2010;24:197–200.
   PubMed Web of Science ®Google Scholar
• Pene-Dumitrescu T, Smithgall TE. Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner. J Biol Chem 2010;285: 21446–21457.
   PubMed Web of Science ®Google Scholar
• Ramchandren R, Schiffer CA. Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia. Biol Targets Ther 2009;3:205–214.
   PubMedGoogle Scholar
• Samanta AK, Chakraborty SN, Wang Y, et al. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene 2009;28:1669–1681.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Hayette S, Lagarde V, et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 2008;68:9809–9816.
   PubMed Web of Science ®Google Scholar
• Rix U, Remsing Rix LL, Terker AS, et al. A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells. Leukemia 2010;24:44–50.
   PubMed Web of Science ®Google Scholar
• Gioia R, Leroy C, Drullion C, et al. Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells. Blood 2011;118:2211–2221.
   PubMed Web of Science ®Google Scholar
• Okabe S, Tauchi T, Tanaka Y, et al. Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line. J Hematol Oncol 2011;4:32.
   PubMed Web of Science ®Google Scholar
• Amsberg GK, Schafhausen P. Bosutinib in the management of chronic myelogenous leukemia. Biol Targets Ther 2013;7:115–122.
   PubMedGoogle Scholar
• Ban K, Gao Y, Amin HM, et al. BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia. Blood 2008;111:2904–2908.
   PubMed Web of Science ®Google Scholar
• Javadi M, Richmond TD, Huang K, et al. CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN. J Biol Chem 2013;288:19459–19470.
   PubMed Web of Science ®Google Scholar
• Bunda S, Kang MW, Sybingco SS, et al. Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia. Cancer Res 2013;73:2540–25450.
   PubMed Web of Science ®Google Scholar
• Chatain N, Ziegler P, Fahrenkamp D, et al. Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells. Oncogene 2013;32:3587–3597.
   Google Scholar
• Gleixner KV, Mayerhofer M, Cerny-Reiterer S, et al. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood 2011;118:1885–1898.
   PubMed Web of Science ®Google Scholar
• Takeda Y, Nakaseko C, Tanaka H, et al. Direct activation of STAT5 by ETV6-LYN fusion protein promotes induction of myeloproliferative neoplasm with myelofibrosis. Br J Haematol 2011; 153:589–598.
   PubMed Web of Science ®Google Scholar
• Bourrie B, Brassard DL, Cosnier-Pucheu S, et al. SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias. Leuk Lymphoma 2013;54:1488–1499.
   PubMed Web of Science ®Google Scholar
• Boehrer S, Galluzzi L, Lainey E, et al. Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia. Cell Cycle 2011;10:3168–3175.
   PubMed Web of Science ®Google Scholar
• Duong VH, Jaglal MV, Zhang L, et al. Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy. Leuk Res 2013;37:300–304.
   PubMed Web of Science ®Google Scholar
• Dos Santos C, McDonald T, Ho YW, et al. The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cell by chemotherapeutic agents. Blood 2013;122:1900–1913.
   PubMed Web of Science ®Google Scholar
• Roginskaya V, Zuo S, Caudell E, et al. Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth. Leukemia 1999;13:855–861.
   PubMed Web of Science ®Google Scholar
• Liu WH, Chang LS. Suppression of ADAM17-mediated Lyn/Akt pathways induces apoptosis of human leukemia U937 cells: Bungarus multicinctus protease inhibitor-like protein-1 uncovers the cytotoxic mechanism. J Biol Chem 2010;285:30506–30515.
   PubMed Web of Science ®Google Scholar
• Dos Santos C, Demur C, Bardet V, et al. A critical role for Lyn in acute myeloid leukemia. Blood 2008;111:2269–2279.
   PubMed Web of Science ®Google Scholar
• Guo Y, Shan Q, Gong Y, et al. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway. Cancer Biol Ther 2012;13:1244–1254.
   PubMed Web of Science ®Google Scholar
• Okamoto M, Hayakawa F, Miyata Y, et al. Lyn is an important component of the signal transduction pathway specific to FLT3//ITD and can be a therapeutic target in the treatment of AML with FLT3//ITD. Leukemia 2007;21:403–410.
   PubMed Web of Science ®Google Scholar
• Robinson LJ, Xue J, Corey SJ. Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations. Exp Hematol 2005;33:469–479.
   PubMed Web of Science ®Google Scholar
• Leischner H, Albers C, Grundler R, et al. SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML. Blood 2012;119:4026–4033.
   PubMed Web of Science ®Google Scholar
• Chien CM, Yang SH, Lin KL, et al. Novel indoloquinoline derivative, IQDMA, suppresses STAT5 phosphorylation and induces apoptosis in HL-60 cells. Chem Biol Interact 2008;176:40–47.
   PubMed Web of Science ®Google Scholar
• Bandi SR, Brandts C, Rensinghoff M, et al. E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease. Blood 2009;114:4197–4208.
   PubMed Web of Science ®Google Scholar
• Jones JE, Wang L, Kropf PL, et al. Src family kinase gene targets during myeloid differentiation: identification of the EGR-1 gene as a direct target. Leukemia 2009;23:1933–1935.
   Google Scholar
• Miranda MB, Redner RL, Johnson DE. Inhibition of Src family kinases enhances retinoic acid–induced gene expression and myeloid differentiation. Mol Cancer Ther 2007;6:3081–3090.
   PubMed Web of Science ®Google Scholar
• Amrein L, Hernandez TA, Ferrario C, et al. Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro. Br J Haematol 2008;143:698–706.
   PubMed Web of Science ®Google Scholar
• Tibaldi E, Brunati AM, Zonta F, et al. Lyn-mediated SHP-1 recruitment to CD5 contributes to resistance to apoptosis of B-cell chronic lymphocytic leukemia cells. Leukemia 2011;25:1768–1781.
   Google Scholar
• Trentin L, Frasson M, Donella-Deana A, et al. Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia. Blood 2008;112:4665–4674.
   PubMed Web of Science ®Google Scholar
• Hussein K, von Neuhoff N, Busche G, et al. Opposite expression pattern of Src kinase Lyn in acute and chronic haematological malignancies. Ann Hematol 2009;88:1059–1067.
   PubMed Web of Science ®Google Scholar
• Frezzato F, Gattazzo C, Martini V, et al. HS1, a Lyn kinase substrate, is abnormally expressed in B-chronic lymphocytic leukemia and correlates with response to fludarabine-based regimen. PloS One 2012;7:e39902.
   Web of Science ®Google Scholar
• Ghosh AK, Secreto C, Boysen J, et al. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood 2011;117:1928–1937.
   PubMed Web of Science ®Google Scholar
• Contri A, Brunati AM, Trentin L, et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 2005;115:369–378.
   PubMed Web of Science ®Google Scholar
• Veldurthy A, Patz M, Hagist S, et al. The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood 2008;112:1443–1452.
   PubMed Web of Science ®Google Scholar
• Silva CM. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004;23: 8017–8023.
   PubMed Web of Science ®Google Scholar
• Redondo-Munoz J, Ugarte-Berzal E, Terol MJ, et al. Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain. Cancer Cell 2010;17: 160–172.
   PubMed Web of Science ®Google Scholar
• Talab F, Allen JC, Thompson V, et al. LCK is an important mediator of B-cell receptor signaling in chronic lymphocytic leukemia cells. Mol Cancer Res 2013;11:541–554.
   PubMed Web of Science ®Google Scholar
• Harr MW, Caimi PF, McColl KS, et al. Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia. Cell Death Differ 2010;17:1381–1391.
   PubMed Web of Science ®Google Scholar
• Ren M, Qin H, Ren R, et al. Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases. Cancer Res 2011;71:7312–7322.
   PubMed Web of Science ®Google Scholar
• Yang J, Liu X, Nyland SB, et al. Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway. Blood 2010;115:51–60.
   PubMed Web of Science ®Google Scholar
• Hu Y, Liu Y, Pelletier S, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004;36:453–461.
   PubMed Web of Science ®Google Scholar
• Fei F, Stoddart S, Muschen M, et al. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia. Leukemia 2010;24:813–820.
   PubMed Web of Science ®Google Scholar
• Spijkers-Hagelstein JA, Mimoso Pinhancos S, Schneider P, et al. Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia. Leukemia 2013;27:1063–1071.
   PubMed Web of Science ®Google Scholar
• De Keersmaecker K, Porcu M, Cox L, et al. NUP214-ABL1 mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins. Haematologica 2014;99:85–93.
   PubMed Web of Science ®Google Scholar
• De Keersmaecker K, Versele M, Cools J, et al. Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases. Leukemia 2008; 22:2208–2216.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Xu CW, Naito M, et al. Regulation of cancer stem cell properties by CD9 in human B-acute lymphoblastic leukemia. Biochem Biophys Res Commun 2011;409:14–21.
   PubMed Web of Science ®Google Scholar
• Nam S, Scuto A, Yang F, et al. Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signaling. Mol Oncol 2012;6:276–283.
   PubMed Web of Science ®Google Scholar